Sample 23

Evaluation Instructions

Task Overview: AI models read clinical trial protocol documents and were asked to extract evidence supporting specific eligibility criteria modifications. You're evaluating whether the AI extracted the RIGHT evidence that justifies the post-modified (final) eligibility criteria.

Workflow: AI reads protocol → AI extracts evidence → Ground truth is final modified criteria → You evaluate if AI's evidence actually supports those final criteria

Important: Some outputs may be low quality and should be scored accordingly.

Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).

Clean view: Shows formatted, readable text for easy comparison
Diff view: Highlights differences between ground truth and prediction
Raw view: Shows original unformatted text as it appears in the dataset

Evaluation scale (0-4):

0 = No match: Prediction is unrelated or contradicts the target criteria
1 = Poor match: Minimal overlap with ground truth, major errors or omissions
2 = Partial match: Some key elements captured, but notable gaps or inaccuracies
3 = Good match: Most elements correct, minor differences or formatting issues
4 = Excellent match: Essentially identical content, fully correct capture

Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.

Ground Truth

INCLUSION CRITERIA

  1. Participant has cancer
  2. Participant is treated with an oral or injectable Food and Drug Administration (FDA)-approved EGFRi or MEKi therapy
  3. Participant has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per common terminology criteria for adverse events (CTCAE) version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.

EXCLUSION CRITERIA

  1. Participant has infected EGFRi/MEKi-associated acneiform rash according to investigator's evaluation.
  2. Note: Other protocol defined Inclusion/

EXCLUSION CRITERIA

  1. may apply.

Prediction

INCLUSION CRITERIA

  1. Subject has cancer
  2. Subject is treated with an oral or injectable FDA-approved EGFRi or MEKi therapy
  3. Subject has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per CTCAE Version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.
  4. Subject is screened for inclusion.

EXCLUSION CRITERIA

  1. Subject has infected EGFRi/MEKi-associated acneiform rash according to Investigator's evaluation.
  2. Subject is unable to comply with study procedures due to COVID-19 related center closures.
  3. Note: Other protocol defined Inclusion/

EXCLUSION CRITERIA

  1. may apply.